FATE · Fate Therapeutics Inc
United States · RS rating 50 · As of 2026-10-14
| Price | 1.94 USD |
|---|---|
| 1-day change | -3.0% |
| RS rating (overall / 1M / 3M / 12M) | 50 / 13 / 12 / 86 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 27 / 54 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | -21.4% |
| Distance from 52-week high | +37.6% |
| Market cap (USD) | $153.5M |